secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001082554-22-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics FY2021 revenue $1.69B (+14% YoY); Tyvaso DPI decision pushed to May 2022
--------------------------------------------------------------------------------

- Full year 2021 revenue $1.69B, up 14% YoY; Q4 revenue $415M, up 8% YoY.
- Net income $475.8M ($10.60 basic GAAP EPS); non-GAAP diluted EPS $15.26.
- Tyvaso net sales $607.5M in 2021, up 26% YoY; Remodulin down 1% to $513.7M.
- Tyvaso DPI NDA extended to May 2022 after FDA requested info on pulmonary safety related to Citizen Petition.
- Patient count reached all-time high; target of 6,000 Tyvaso patients by end of 2022 reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255422000006/0001082554-22-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255422000006/uthr-20220224.htm
  HTML page:      https://secwatch.observer/filing/0001082554-22-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer